 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
The company has a drug called 3TC effective in an Aids cocktail mix with Glaxo's drug and maybe even some of Mercs new drug. It has been very volatile because of much controversity and misunderstanding. The drug is also very effective against hepatitis Both potential markets are huge. Still considered untaped yet. The stock is rated a very agressive buy by Hambrect and Quist. BCHXF has a composition of matter patent. Yet Emory university was granted a patent for 3TC. Biochem Pharm will fight the granting of the patent to Emory Univ. Because of other patent rights and other legal matters even if the Emory patent is retained it will only effect a small % of the profits of BCHXF. The stock closed at 28 tonight. It sold off on what I believe to be a buy of 100,000 shares at 29 then several 10,000 share lots hitting the bid at 28. I feel it is a panic sell at 28 and should be brought here. If it goes lower still a buy. Jerry. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |